These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. Sanz E; Romera M; Bellik L; Marco JI; Unzeta M Med Sci Monit; 2004 Dec; 10(12):BR477-84. PubMed ID: 15567979 [TBL] [Abstract][Full Text] [Related]
5. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. Mytilineou C; Leonardi EK; Radcliffe P; Heinonen EH; Han SK; Werner P; Cohen G; Olanow CW J Pharmacol Exp Ther; 1998 Feb; 284(2):700-6. PubMed ID: 9454817 [TBL] [Abstract][Full Text] [Related]
6. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Magyar K; Szende B Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898 [TBL] [Abstract][Full Text] [Related]
7. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]. Pálfi M; Szökó E; Kálmán M Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880 [TBL] [Abstract][Full Text] [Related]
8. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508]. Miklya I Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016 [TBL] [Abstract][Full Text] [Related]
9. Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant. Seif-El-Nasr M; Atia AS; Abdelsalam RM Arzneimittelforschung; 2008; 58(4):160-7. PubMed ID: 18540477 [TBL] [Abstract][Full Text] [Related]
10. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. Engberg G; Elebring T; Nissbrandt H J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311 [TBL] [Abstract][Full Text] [Related]
11. Anti-apoptotic effect of esculin on dopamine-induced cytotoxicity in the human neuroblastoma SH-SY5Y cell line. Zhao DL; Zou LB; Lin S; Shi JG; Zhu HB Neuropharmacology; 2007 Nov; 53(6):724-32. PubMed ID: 17904593 [TBL] [Abstract][Full Text] [Related]
14. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B]. Knoll J Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565 [TBL] [Abstract][Full Text] [Related]
15. Perturbation of dopamine metabolism by 3-amino-2-(4'-halophenyl)propenes leads to increased oxidative stress and apoptotic SH-SY5Y cell death. Samms WC; Perera RP; Wimalasena DS; Wimalasena K Mol Pharmacol; 2007 Sep; 72(3):744-52. PubMed ID: 17576792 [TBL] [Abstract][Full Text] [Related]
16. MPP(+) increases the vulnerability to oxidative stress rather than directly mediating oxidative damage in human neuroblastoma cells. Lee HS; Park CW; Kim YS Exp Neurol; 2000 Sep; 165(1):164-71. PubMed ID: 10964495 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Kostrzewa RM; Kostrzewa JP; Brus R Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519 [TBL] [Abstract][Full Text] [Related]
18. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Naoi M; Maruyama W Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610 [TBL] [Abstract][Full Text] [Related]
19. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation. Legros H; Dingeval MG; Janin F; Costentin J; Bonnet JJ Neurotoxicology; 2004 Mar; 25(3):365-75. PubMed ID: 15019299 [TBL] [Abstract][Full Text] [Related]
20. Extracellular dopamine induces the oxidative toxicity of SH-SY5Y cells. Jiang Y; Pei L; Li S; Wang M; Liu F Synapse; 2008 Nov; 62(11):797-803. PubMed ID: 18720420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]